Key facts
- This page summarizes Mitchell E. Levinson's Form 4 filing for Pulse Biosciences, Inc. (PLSE).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 09 May 2023, 21:46.
Mitchell E. Levinson - 17 Apr 2023 Form 4 Insider Report for Pulse Biosciences, Inc. (PLSE)
- Reporting relationship
- Chief Strategy Officer, Director
- Issuer ticker
- PLSE
- Reported as of
- 17 Apr 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 May 2023, 21:46:31 UTC
- Prior SEC filing
- 11 Oct 2022
- Next SEC filing
- 06 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Kenneth B. Stratton, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Mitchell E. Levinson filed Form 4 for Pulse Biosciences, Inc. (PLSE) on 09 May 2023.
Change
- Previous filing in this sequence was filed on 11 Oct 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
PLSE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +17,700
- Change %
- Price
- Shares after
- 17,700
- Date
- 08 May 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,700
- Exercise price
- $8.02
- Footnotes
- F1, F2
PLSE
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- Shares
- +2,000
- Change %
- Price
- Shares after
- 2,000
- Date
- 17 Apr 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 2,000
- Exercise price
- $5.81
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The option was granted on May 8, 2023 under the Issuer's 2017 Equity Incentive Plan. The shares subject to the option are subject to performance-based vesting criteria. 4,425 shares will vest in equal annual installments over the following four years, subject to achievement of the vesting criteria and the reporting person's continued service through each vesting date.
Footnote F2
Not applicable.